Toggle

Allogeneic (cells from a donor) blood or marrow transplant (BMT) using reduced-intensity preparation and a drug, cyclophosphamide, after transplant to treat blood cancers

Print

75 and younger

Phase 2

1 Location

NCT05805605

Clinical Trial Goal


To find out if reduced-intensity allogeneic BMT with post-transplant cyclophosphamide is safe and works well to treat blood cancers.

You may be able to join this trial if you:


  • Are 75 years old or younger
  • Have a blood cancer. Some examples include:
    • Acute lymphocytic leukemia (ALL)
    • Acute myeloid leukemia (AML)
    • Chronic lymphocytic leukemia (CML)
    • Chronic myeloid leukemia (CLL)
    • Multiple myeloma
    • Myelodysplastic syndrome (MDS)
    • Myelofibrosis
    • Myeloproliferative neoplasm (MPN)
    • Non-Hodgkin lymphoma (NHL) including:
      • Burkitt lymphoma
      • Follicular lymphoma
      • Marginal zone lymphoma (MZL)
      • T-cell lymphoma (TCL)
    • Plasma cell leukemia
  • Have not had an allogeneic BMT in the last 3 months
  • Agree to have other standard tests done to see if you can be in the clinical trial

Trial Details


Cyclophosphamide is a chemotherapy (chemo) drug that helps prevent GVHD and blocks the growth of cancer cells.
Fludarabine is a chemo drug that blocks the growth of cancer cells.
Mycophenolate mofetil and sirolimus are drugs that slow down the immune system.

Before transplant, you’ll get standard treatment with the following:
  • Cyclophosphamide – Given as an intravenous (IV) infusion 1 time
  • Fludarabine – Given as IV infusions 1 time each day for 5 days
  • Total body irradiation (TBI) – A treatment done 1 time, the day before transplant to prepare your body for transplant

On transplant day, the blood-forming cells from your donor are given to you through an IV infusion.

After transplant, you’ll get:
  • Cyclophosphamide – Given as an IV infusion 1 time each day for 2 days
  • Mycophenolate mofetil - Give as an IV infusion or pill you take by mouth for about 1 month 
  • Sirolimus - A pill that you take by mouth for 2 months

You'll have biopsies and/or scans to see how well the treatment is working. The clinical trial doctors will check your health for up to 3 years. 

The Food and Drug Administration (FDA) has approved all of the drugs used in this trial. 

Contacts


Mark Juckett, 6126255469, juck0001@umn.edu

Locations


Masonic Cancer Center at University of MinnesotaRECRUITING

Minneapolis, Minnesota
Mark Juckett

ClinicalTrials.gov record


NCT05805605. First posted on 4/10/23

Call center employee on the phone offering help to a caller

Questions? Contact our Clinical Trials Navigator

1-888-814-8610
contact@ctsearchsupport.org